WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will...

WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent...

Key milestones across our chronic hepatitis B virus (cHBV) and  pan-coronavirus programs remain on track Financially strong with a projected cash runway into the  second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug....

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second...

Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a...

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after...

Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET WARMINSTER, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology...

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...

WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will...

WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a...